Stock Market Reviews

AZTR (Azitra, Inc.) News

Get the latest news, insights, and market updates on AZTR (Azitra, Inc.). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• AZTR: ATR-04 Trial to Dose 1st Patient Mid-2025
  By John Vandermosten, CFA NYSE:AZTR READ THE FULL AZTR RESEARCH REPORT Azitra, Inc. (NYSE:AZTR) reported first quarter 2025 results in a May 13 th  press release sharing financial results and providing a business update. Year to date, the company has presented posters at multiple scientific conferences, entered into a purchase agreement to raise additional capital and is looking ahead to
  May 21, 2025 - $AZTR
• Azitra, Inc. to Present Abstract at American Society of Gene and Cell Therapy Highlighting Phase 1/2 Study Targeting Cancer Therapy-Associated Rash
  Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it will present a poster describing the Phase 1/2 clinical trial of ATR04-484 for EGFR inhibitor ("EGFRi")-associated rash at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT). ASGCT is being held May 13-17, 2025, in New Orleans, Louisiana.
  May 14, 2025 - $AZTR
• Azitra, Inc. Announces Q1 2025 Results and Provides Business Updates
  Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the quarter ended March 31, 2025, and provided a business update.
  May 13, 2025 - $AZTR